Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
Pulmonx (Nasdaq: LUNG) will release its second quarter 2026 financial results after market close on Wednesday, July 29, 2026.
Rhea-AI Summary
Pulmonx (Nasdaq: LUNG) will release its second quarter 2026 financial results after market close on Wednesday, July 29, 2026. Company management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, with live and archived webcast access via the Investors section of the Pulmonx website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – LUNG
On Jul 16, the first trading day after this news, LUNG closed 0.69% above the previous close. Our momentum scanner recorded 5 alerts for this stock that day.
Data tracked by StockTitan Argus for the Jul 16 session.
Key Figures
- Earnings release date
- July 29, 2026
- Second quarter 2026 financial results release after market close
- Conference call time
- 1:30 p.m. PT / 4:30 p.m. ET
- Management call to discuss Q2 2026 results
Previous Earnings date Reports
-
Scheduled first quarter 2026 results and related earnings call details.
-
Announced Q4 and full year 2025 results date and conference call timing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2026 after the close of trading on Wednesday, July 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.pulmonx.com.
Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston or Webb Campbell
Gilmartin Group
investors@pulmonx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.